Advanced Search

Journal of Traditional Chinese Medicine >

2026 , Vol. 46 >Issue 4: 854 - 863

DOI: https://doi.org/10.19852/j.cnki.jtcm.20260514.002

Original Articles

Therapeutic effect of Fuzheng Yixin decoction (扶正益心方) on cardiac insufficiency via the soluble guanylyl cyclase-cyclic guanosine monophosphate-protein kinase G pathway in a doxorubicin-induced dilated cardiomyopathy rat model

  • SANG Xiuxiu ,
  • Lü Shuquan ,
  • WANG Feng ,
  • YANG Jing ,
  • WANG Qingguo ,
  • WANG Lixin
Expand
  • 1 Graduate School, Hebei University of Chinese Medicine, Shijiazhuang 050000, China
    2 Department of Cardiology, Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Cangzhou 061000, China
    3 Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China

Received date: 2025-06-13

  Accepted date: 2025-10-13

  Online published: 2026-05-14

Supported by

Hebei Province Graduate Student Innovation Funding Program: Exploring the Mechanism of Action of Fuzheng Yixin decoction in Treating Dilated Cardiomyopathy Based on Omics and Network Pharmacology(XCXZZBS2025041);Hebei Administration of Traditional Chinese Medicine Funding Program: Exploring the Effects and Mechanisms of Fuzheng Yixin decoction in Treating Dilated Cardiomyopathy Based on Metabolomics(2025562)

Fold

Abstract

OBJECTIVE: To investigate the effect of Fuzheng Yixin decoction (扶正益心方, FZYX) and explore its underlying mechanisms in doxorubicin-induced dilated cardiomyopathy (DCM) rat model.

METHODS: Sprague-Dawley rats were intraperitoneally injected with doxorubicin for 6 consecutive weeks. Ultra-high-perform ance liquid chromatography Q-exactive mass spectrometry was utilized to obtain mass spectrum data for FZYX. The rats were then intragastrically injected with low-dose FZYX, high-dose FZYX, or captopril for 4 weeks. Serum N-terminal pro-brain natriuretic peptide, transthoracic echocardiography, haematoxylin and eosin and Masson staining, electron microscopy, and immunohistochemistry were used to evaluate the efficacy of FZYX. Differentially expressed genes and metabolites in the myocardial tissue of DCM rats following FZYX intervention were subsequently identified through transcriptomics and non-targeted metabolomics. Finally, the influence of FZYX on the expression of natriuretic peptide precursor A (Nppa), natriuretic peptide precursor B (Nppb), soluble guanylyl cyclase (sGC), protein kinase G (PKG), and PKG-1α in DCM rats was verified through quantitative polymerase chain reaction (qPCR), Western blotting (WB) based on the results of transcriptomics and non-targeted metabolomics analyses.

RESULTS: FZYX alleviated body weight loss; inhibited ventricular dilatation; restored impaired heart function, ruptured sarcomeres and mitochondrial damage, and pathological changes; and reduced collagen deposition. Transcriptomic and non-targeted metabolomic results revealed that FZYX regulated the expression of sGC-cyclic guanosine monophosphate (cGMP)-PKG pathway-related genes (Nppa, Nppb) and metabolites such as cGMP, 5'-guanylic acid, adenosine. qPCR and WB demonstrated that FZYX suppressed the expression of Nppa and Nppb and increased the expression of sGC, which led to a further increase in the level of PKG and PKG-1α.

CONCLUSION: These findings suggest that the cardioprotective effect of FZYX may be mediated through the restoration of the sGC-cGMP-PKG signaling pathway. FZYX may provide a new strategy for clinical application against DCM.

Key words： dilated cardiomyopathy; transcriptomics; non-targeted metabolomics; soluble guanylyl cyclase-cyclic guanosine monophosphate-protein kinase G pathway

Cite this article

SANG Xiuxiu , Lü Shuquan , WANG Feng , YANG Jing , WANG Qingguo , WANG Lixin . Therapeutic effect of Fuzheng Yixin decoction (扶正益心方) on cardiac insufficiency via the soluble guanylyl cyclase-cyclic guanosine monophosphate-protein kinase G pathway in a doxorubicin-induced dilated cardiomyopathy rat model[J]. Journal of Traditional Chinese Medicine, 2026 , 46(4) : 854 -863 . DOI: 10.19852/j.cnki.jtcm.20260514.002

References

1. Orphanou N, Papatheodorou E, Anastasakis A. Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments. Heart Fail Rev 2022; 27: 1173-91.
2. Jordan E, Peterson L, Ai T, et al. Evidence-based assessment of genes in dilated cardiomyopathy. Circulation 2021; 144: 7-19.
3. Heymans S, Lakdawala NK, Tsch?pe C, et al. Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches. Lancet 2023; 402: 998-1011.
4. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J 2023; 44: 3503-626.
5. Harding D, Chong MHA, Lahoti N, et al. Dilated cardiomyopathy and chronic cardiac inflammation: pathogenesis, diagnosis and therapy. J Intern Med 2023; 293: 23-47.
6. Chinese Society of Cardiology, Chinese Myocarditis Cardiomyopathy Collaborative Group. Chinese guidelines for the diagnosis and management of dilated cardiomyopathy. J Clin Cardiol 2018; 34: 421-34.
7. Mangmool S, Duangrat R, Parichatikanond W, et al. New therapeutics for heart failure: focusing on cGMP signaling. Int J Mol Sci 2023; 24: 12866.
8. Sun R, Zhang Y, Li X, et al. Investigation of effects of Traditional Chinese Medicine astragalus heart-protecting decoction on rats with dilated cardiomyopathy. All Life 2021; 14: 846-54.
9. Sun R, Wang J, Zheng Y, et al. Traditional Chinese Medicine Baoxin decoction improves cardiac fibrosis of rats with dilated cardiomyopathy. Exp Ther Med 2017; 13: 1900-6.
10. Wei J, Li B, Wang X, et al. Efficacy and safety of Qili Qiangxin capsule on dilated cardiomyopathy: a systematic review and Meta-analysis of 35 randomized controlled trials. Front Pharmacol 2022; 13: 893602.
11. Wu Q, An S, Lee RJ, et al. Efficacy and safety of Kuoxin formula in the treatment of dilated cardiomyopathy-related heart failure: study protocol of a randomized, double-blind, placebo-controlled, multi-center clinical trial. Int J Gen Med 2024; 17: 1909-21.
12. Cao X, Liu H, Zhou M, Chen X, Long D. Comparative efficacy of five Chinese medicine injections for treating dilated cardiomyopathy with heart failure: a Bayesian network Meta-analysis. J Ethnopharmacol 2022; 282: 114604.
13. Zhu YS, Li YL, Ju JQ, Du F, et al. Oral Chinese herbal medicine for treatment of dilated cardiomyopathy: a systematic review and Meta-analysis. Evid Based Complement Altern Med 2016; 2016: 1819794.
14. Ajay A, Rasoul D, Abdullah A, et al. Augmentation of natriuretic peptide (NP) receptor A and B (NPR-A and NPR-B) and cyclic guanosine monophosphate (cGMP) signalling as a therapeutic strategy in heart failure. Expert Opin Investig Drugs 2023; 32: 1157-70.
15. Nakamura T, Tsujita K. Current trends and future perspectives for heart failure treatment leveraging cGMP modifiers and the practical effector PKG. J Cardiol 2021; 78: 261-8.
16. Zhang S, Wei X, Zhang H, et al. Doxorubicin downregulates autophagy to promote apoptosis-induced dilated cardiomyopathy via regulating the AMPK/mTOR pathway. Biomed Pharmacother 2023; 162: 114691.
17. Tomczyk MM, Cheung KG, Xiang B, et al. Mitochondrial sirtuin-3 (SIRT3) prevents doxorubicin-induced dilated cardiomyopathy by modulating protein acetylation and oxidative stress. Circ Heart Fail 2022; 15: e008547.
18. Kciuk M, Gielecińska A, Mujwar S, et al. Doxorubicin-an agent with multiple mechanisms of anticancer activity. Cells 2023; 12: 659.
19. Rawat PS, Jaiswal A, Khurana A, et al. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother 2021; 139: 111708.
20. Li X, Xu G, Wei S, et al. Lingguizhugan decoction attenuates doxorubicin-induced heart failure in rats by improving TT-SR microstructural remodeling. BMC Complement Altern Med 2019; 19: 360.
21. Yang M, Wu H, Qian H, et al. Linggui Zhugan decoction delays ventricular remodeling in rats with chronic heart failure after myocardial infarction through the Wnt/β-catenin signaling pathway. Phytomedicine 2023; 120: 155026.
22. Podyacheva EY, Kushnareva EA, Karpov AA, Toropova YG. Analysis of models of doxorubicin-induced cardiomyopathy in rats and mice. A modern view from the perspective of the pathophysiologist and the clinician. Front Pharmacol 2021; 12: 670479.
23. Shen LJ, Lu S, Zhou YH, Li L, Xing QM, Xu YL. Developing a rat model of dilated cardiomyopathy with improved survival. Zhejiang Da Xue Xue Bao 2016; 17: 975-83.
24. Suliman HB, Carraway MS, Ali AS, Reynolds CM, Welty-Wolf KE, Piantadosi CA. The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy. J Clin Invest 2007; 117: 3730-41.
25. Frangogiannis NG. Cardiac fibrosis. Cardiovasc Res 2021; 117: 1450-88.
26. Ricard-Blum S. The collagen family. Cold Spring Harb Perspect Biol 2011; 3: a004978.
27. Ma S, Li X, Dong L, Zhu J, Zhang H, Jia Y. Protective effect of Sheng-Mai Yin, a traditional Chinese preparation, against doxorubicin-induced cardiac toxicity in rats. BMC Complement Altern Med 2016; 16: 61.
28. Sun XT, Song YJ, Xie Y, et al. Shenlijia attenuates doxorubicin-induced chronic heart failure by inhibiting cardiac fibrosis. Evid Based Complement Altern Med 2021; 2021: 6659676.
29. Xu S, Wang Y, Yu M, et al. Longshengzhi capsule inhibits doxorubicin-induced heart failure by anti-oxidative stress. Biomed Pharmacother 2020; 123: 109803.
30. Evora PRB, Evora PM, Celotto AC, Rodrigues AJ, Joviliano EE. Cardiovascular therapeutics targets on the NO-sGC-cGMP signaling pathway: a critical overview. Curr Drug Targets 2012; 13: 1207-14.
31. Chen H, Levine YC, Golan DE, Michel T, Lin AJ. Atrial natriuretic peptide-initiated cGMP pathways regulate vasodilator-stimulated phosphoprotein phosphorylation and angiogenesis in vascular endothelium. J Biol Chem 2008; 283: 4439-47.
32. Reiss AB, Grossfeld D, Kasselman LJ, et al. Adenosine and the cardiovascular system. Am J Cardiovasc Drugs 2019; 19: 449-64.
33. Cho H, Zhao XX, Lee S, et al. The sGC-cGMP signaling pathway as a potential therapeutic target in doxorubicin-induced heart failure: a narrative review. Am J Cardiovasc Drugs 2022; 22: 117-25.
34. Chen W, Wu Y, Li W, et al. Vericiguat improves cardiac remodelling and function in rats with doxorubicin-induced cardiomyopathy. ESC Heart Fail 2025; 12: 1807-17.
35. Castro LR, Verde I, Cooper DM, Fischmeister R. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 2006; 113: 2221-8.
36. Preedy ME, Baliga RS, Hobbs AJ. Multiplicity of nitric oxide and natriuretic peptide signaling in heart failure. J Cardiovasc Pharmacol 2020; 75: 370-84.
37. Dunkerly-Eyring B, Kass DA. Myocardial phosphodiesterases and their role in cGMP regulation. J Cardiovasc Pharmacol 2020; 75: 483-93.
38. Giovou AE, Gladka MM, Christoffels VM. The impact of natriuretic peptides on heart development, homeostasis, and disease. Cells 2024; 13: 931.
39. Chen L, Zhou X, Deng Y, et al. Zhenwu decoction ameliorates cardiac hypertrophy through activating sGC (soluble guanylate cyclase)-cGMP (cyclic guanosine monophosphate)-PKG (protein kinase G) pathway. J Ethnopharmacol 2023; 300: 115705.
40. Qin L, Zang M, Xu Y, et al. Chlorogenic acid alleviates hyperglycemia-induced cardiac fibrosis through activation of the NO/cGMP/PKG pathway in cardiac fibroblasts. Mol Nutr Food Res 2021; 65: 2000810.
41. Koka S, Das A, Zhu SG, Durrant D, Xi L, Kukreja RC. Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. J Pharmacol Exp Ther 2010; 334: 1023-30.
Options
Outlines

/

〈 〉